Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 4/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.52 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | ADAM17 | P78536 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6023580 | 0.91 | ADAM17 (0.55) | ADAMTS4MMP13ADAM17 | |
| SCHEMBL6023378 | 0.86 | ADAM17 (0.56) | ADAMTS4MMP13ADAM17 | |
| SCHEMBL5036449 | 0.85 | ADAM17 (0.48) | ADAMTS4MMP13ADAM17 | |
| SCHEMBL6022835 | 0.84 | ADAM17 (0.54) | MMP13ADAM17 | |
| SCHEMBL6023809 | 0.82 | MMP13 (0.52) | ADAMTS4MMP13ADAM17 | |
| SCHEMBL6023772 | 0.81 | ADAM17 (0.61) | ADAMTS4MMP13ADAM17 | |
| SCHEMBL6023498 | 0.81 | ADAM17 (0.48) | ADAMTS4MMP13ADAM17 | |
| SCHEMBL6023495 | 0.81 | ADAM17 (0.48) | ADAMTS4MMP13ADAM17 | |
| Trifluoroacetic Acid SCHEMBL6023787 | 0.81 | ADAM17 (0.44) | ITGB3ITGA2BADAMTS4MMP13ADAM17 | |
| SCHEMBL6024023 | 0.81 | ADAM17 (0.47) | ADAMTS4MMP13ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125870-B2 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| US-20040122005-A1 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-24 | — | — | US | disclosed |
| WO-2004043349-A2 | ISOXAZOLINE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122005-A1 | Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | MMP2, MMP1, MMP9 | MIF 222/4885ITGB3 1006/4885ITGA2B 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.